Chronic Myelomonocytic Leukemia with t (3; 9) (p21; p13) as a Sole Abnormal Appearance: One Case Report

Ji-hong ZHANG  
Li-jun GUAN  
Yun-xiu WANG  
Ying-chun ZHENG  
Nan ZHANG  
Hai-xia TONG

Hematology Laboratory, Hematology Malignancy Treatment Center, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China.

Correspondence to: Ji-hong ZHANG  
E-mail: Zhangjihong_cmu@yahoo.cn

Introduction

Chronic myelomonocytic leukemia, (CMML) is a clinically rare chronic myeloid leukemia, with an incidence rate of about 1-2/100,000/year, and the age of the predominant cases is over 60 years. The median age of onset is 65-70 years, and the ratio of the incidence between male and female is about 1.5 : 3.1. Specific etiological factors of the disease are not clear, but may be associated with the exposure to ionizing radiation, occupational and environmental carcinogens, or toxins. The FAB (French-American-British) Cooperative Group defined CMML as a subtype of myelodysplastic syndrome (MDS)[1]. Since it has both characters of bone marrow abnormal proliferation and bone marrow dysplasia, recently, the FAB Cooperative Group has classified CMML into myelodysplastic/myeloproliferative diseases (MDS/MPD)[2,3], based on the classification of neoplastic diseases of the hematopoietic and lymphoid tissue. CMML is a malignant-clone disease, which involves bone marrow hematopoietic stem cells, but no specific chromosomal abnormalities are involved. The most common chromosomal abnormalities are +8, -7/7q-, and the structural abnormality is 12p. The chromosomal abnormality found in t (3; 9) (p21; p13) is very rare in hematologic malignancy. So far, only 1 case with acute lymphoblastic leukemia (ALL) has been reported both in China and abroad[4]. A CMML patient with genetic abnormality at t (3; 9) (p21; p13) was admitted and treated in our hospital. The case is reported as follows with a associated literature review.

Case Report

A 75-year-old male was admitted to our hospital for a reducible mass in his left inguinal groove for 2 months. Doctors firstly made diagnosis as left oblique inguinal hernia and prepared to give an operation to the patient. Physical examinations showed mild anemia, no yellow stain of skin and mucus membranes. Superficial lymph nodes could not be touched, and sternum tenderness was negative. There were no abnormalities in heart and lung function, and there was no tenderness and rebound tenderness in the abdomen. Liver could not be palpated...
along the costal margin, and the spleen enlarged about
2 cm under the lower costal. No edema of the limb ex-
tremities was found. X-ray and ECG didn’t show any
abnormalities of the target organs, and B-mode ultrason-
ography of abdomen showed splenomegaly. Blood rou-
tine test (BRT) showed white blood cell (WBC) count
17.8 × 10^9/L, hemoglobin (Hb) concentration 72 g/L,
platelet (PLT) 699 × 10^9/L. Based on the findings of the
examinations, such as BRT abnormality and splenomeg-
aly, the patient was given a surgery. The patient was also
suggested to receive bone marrow puncture for further
diagnosis.

Bone marrow was aspirated about 0.5 mL from poste-
rior superior iliac spine of the patient. The smears were
simultaneously stained with Wright-Giemsa method.
We observed the findings: obviously active proliferation
of the bone marrow, myeloblast accounting for 4.4%,
developmental disorder of nucleus and cytoplasm in
parts of promyelocytes, pelger deformity, and vacuolus
degeneration. The ratio of the eosinophils in the periph-
eral blood increased to 14.4%. Monocytes accounted
for 22.8%, with 8.4% original monocytes and pro-
monocytes. Erythroid proliferation was active, including
megaloblastoid change, monoblasts division, sister
nucleus of erythrocytes, 2 and 3 nuclear of erythrocytes.
Seventeen platelet-forming megakaryocytes were found
around the whole smear. Small megakaryocyte, mega-
karyocytes with multiple round nucleolus and large
platelets could also be seen. Cytochemistry myelopero-
oxidase (MPO) and alkaline phosphatase (NAP) staining:
POX (peroxidase) showed weakly positive; the positive
rate of serum NAP was 44%, with labeling index of 144
points. According to FAB classification and morphology,
the leukemia patient was considered as CMML-II-type
(Fig.1).

Examination of molecular biology
As CMML was a chronic myeloproliferative disease,
BCR-ABL fusion gene and JAK2 gene mutation should
be checked. Nested RT-PCR was used for detecting the
transcript of BCR-ABL fused gene. Results showed: no
BCR-ABL fusion gene transcripts in the sample, which
verified the diagnosis of CMML. Real-Time 7500 PCR
(ABI) was used to check whether the JAK2 gene had
mutation or not, and the detection kit was purchased
from Huaguan Shanghai Biochip Co. Ltd. Results
showed wild-type JAK2 gene (+), mutant JAK2 gene
(-), therefore, the JAK2 gene mutation didn’t occur.

Conventional karyotype analysis
Direct method and 24-h culture for karyotype analysis
were used for conventional chromosome preparation,
and RHG-banding was used to analyze the chromosome,
in which 20 cells of metaphase were analyzed. For im-
age acquisition, the Cycovision Karyotype Analysis
System of AI company in the USA was applied, and the
identification and description of karyotype abnormalities
were based on the International System for Human Cy-
togenetic Nomenclature (ISCN 2005). The karyotype of
the patient was 46, xy, t (3; 9) (p21; p13) (Fig.2).

Since the diagnosis of CMML, the patient only ac-
cepted supportive therapy, such as blood transfusion.
Till July, 2009, the patient suddenly presented fever and
dyspnea, and was admitted to hospital for the second
time. Routine blood test showed that WBC increased to 71.0 × 10⁹/L. Mildly enlarged spleen was detected. The patient refused to have bone marrow aspiration due to his early diagnosis of CMML. The patient accepted chemotherapy, in which hydroxyurea was employed. Two weeks after the chemotherapy, the condition of the patient was obviously improved, with the blood routine test returning to the initial level of preliminary diagnosis. The patient was still under follow up.

Discussion

CMML is a kind of malignant disease of bone marrow clonal hematopoietic stem cell, with both features of myelodysplastic syndrome (MDS) and chronic myeloproliferative disease (MPD). It was firstly classified in MDS in 1982 by French-American-British (FAB) classification system. However, CMML seems out of place from other 4 entities due to the hematologic and morphologic features of CMML varying from predominant myelodysplasia to main myelosis. In 2001, the WHO classification moved CMML from MDS to a new category of mixed MDS/MPD, and also defined CMML I and CMML II according to medullary and peripheral blast counts[12]. This new category of CMML made in 2001 WHO was not substantively changed when revised in 2008 WHO[3].

In recent years, more and more genetics researches have focused on CMML. According to current statistic data, about 20%-30% of CMML patients have genetic abnormalities, including abnormalities in chromosome number or structure, for instance +1, +8, del (20q), -7/7q-, del (11q), del (16q), t (5; 12) (q33; p13), t (5; 7) (q33; q11.2), t (11; 16) (q23; p13), t (1; 13) (p36; q21), t (7; 11) (p15; q21), t (8; 9) (p11; q34), et al.[19] and some of which can be rarely seen in myeloproliferative disorder or myelodysplastic syndromes. In addition, some new genetic abnormality has been reported in recent years, such as der (14) t (1; 14) (q12; p11)[3], t (5; 21) (q13; q22)[20], and der (9) t (1; 9) (q11; q34)[7]. This CMML case showed a sole abnormality of t (3; 9) (p21; p13), which has never been reported in the literature. This translocation of chromosomes is a very rare genetic abnormality in hematologic malignancies, which was currently found in a case with ALL[8].

The breakpoint of t (3; 9) (p21; p13) generates at 3p21 and 9p13. As far as we know, a variety of tumor suppressor genes have been detected in the region of 3p21, among which DNA mismatch repair genes (MLH1), LIMD1 gene and leucyl tRNA synthetase gene (LARS2) can be commonly seen. The 3 genes are closely related to the occurrence and development of esophageal squamous cell carcinoma, colorectal cancer, lung cancer, and nasopharyngeal carcinoma, respectively[8-11].

In the condition of 3p21 breakage, one or more tumor suppressor genes could be lost, which induces the occurrence of different tumors. The breakage of 3p21 region has been reported in chronic myeloid leukemia with the abnormality of t (3; 9) (p21; q11)[12]. Otherwise, it has been reported that familial melanoma predisposing gene (MLM) is located in the region of 9p13 as a kind of oncogene, which is closely related to the occurrence and development of laryngeal squamous cell carcinoma[13]. The breakage at 9p13 region in ALL patients has been found and reported, and most presently, it has been found and reported in malignant hematological patients[14].

According to the analysis above, the abnormality of t (3; 9) (p21; p13) occurring in this case may lead to losing tumor suppressor genes located in the upper part of short arm of chromosome 3, or lead to increasing the amplification of oncogene located in the short arm of chromosome 9, and all these probably result in the occurrence of CMML in this case. The abnormality of t (3; 9) (p21; p13) could occur not only in ALL patients, but also in CMML patients. Unfortunately, our study is lack of data regarding other cytogenetic abnormalities, such as alteration in the RAS pathway that have been frequently found in CMML[15]. Such information may be helpful in further elucidating the molecular biology of the disease.

This is the first CMML case with t (3; 9) (p21; p13) as a sole abnormality. Although more cases are needed to investigate the molecular pathogenesis of this rare transformation in hematologic malignancy, we suggest that t (3; 9) (p21; p13) could be a recurrent chromosomal aberration in myeloid neoplasms, particularly in monocytic-lineage leukemia. Further studies are needed to evaluate the prognosis, survival, and treatment response of the CMML cases with t (3; 9) (p21; p13) abnormality.

Conflict of interest statement

No potential conflicts of interest were disclosed.

References

6. Liu S, Li CW, Bo LJ, et al. AML1/RUNX1 fusion gene and t (5;21) (q13;q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia.
12. Liu S, Li CW, Bo LJ, et al. AML1/RUNX1 fusion gene and t (5;21) (q13;q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia.
Chronic Myelomonocytic Leukemia with t(3;9)(p21;p13) as a Sole Abnormal Appearance: One Case Report

Ji-hong ZHANG, Li-jun GUAN, Yun-xiu WANG, Ying-chan ZHENG, Nan ZHANG, Hai-xia TONG

Hematology Laboratory, Hematology Malignancy Treatment Center, Shengjing Hospital, China

CLINICAL ONCOLOGY AND CANCER RESEARCH

2010, 07(5)

1. Zhang CY; Wu XX Chronic myelomonocytic leukemia 2008
3. Germing U; Strupp C; Knipp S Chronic myelomonocytic leukemia in the light of the WHO proposals 2007(7)
4. Moyer C; Brieger A; Plotz G An interstitial deletion at 3p21.3 results in the genetic fusion of MLH1 and ITGA9 in a Lynch syndrome family 2009
5. Dhingra B; Bhargava R; Mishra P Acute lymphoblastic leukaemia with unusual Chromosomal abnormality: t (3,9) (p21, p13), del (10p12) 2009
7. Lundin C; Heidenblad M; Strombeck B Tiling resolution array CGH of dic(7,9)(p11 approximately 13, p11 approximately 13) in B-cell precursor acute lymphoblastic leukemia reveals clustered breakpoints at 7p11.2 approximately 12.1 and 9p13.1 2007(1)
9. Tan J; Cang S; Seiter K t (3,9,22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis 2009(7)
10. Sharp TV; Al-Attar A; Foxler DE The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development 2008(50)
11. Zhou W; Feng X; Li H Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma 2009
12. Suh B; Park TS; Kim JS Chronic myelomonocytic leukemia with der (9) t (1,9) (q11,q34) as a sole abnormality 2009
13. Liu S; Li CW; Bo LJ AML/RUNX1 fusion gene and t (5,21) (q13,q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia and monocytosis 2004
14. Djordjevic V; Jankovic G; Suwajdziec N A der(14)t (1,14) (q12,p11) in chronic myelomonocytic leukemia 2005
15. Emanuel PD Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia 2008

http://d.g.wanfangdata.com.cn/Periodical_zgzllc-e201005010.aspx